UCBJY News and Press, UCB S.A. ADR From 06/14/19

BRUSSELS , June 14, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced new Phase 2b data on the company's key pipeline molecule, bimekizumab – a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F ...

BRUSSELS and ATLANTA , May 20, 2019 /PRNewswire/ -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company's newest anti-epileptic drug (AED) NAYZILAM ® (midazolam) nasal spray CIV, a benzodiazepine indicated f...

THOUSAND OAKS, Calif. and BRUSSELS , April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopau...

BRUSSELS , March 28, 2019 /PRNewswire/ --   UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA ® (certolizumab pegol) to include a new indication for the treatment of adul...

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These positive results mark the longest-term data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks with investigational molecule bi...

Late breaking presentation of the Phase 2b long-term findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderate-to-severe plaque psoriasis Long-term data from Phase 3 studies CIMPASI-1, CIMPASI-2 and CIMPACT highlight the s...

Background Amgen ( AMGN ) has the same sort of problem that two of my somewhat struggling biotech longs have: old blockbusters with biosimilar threats. (These are AbbVie ( ABBV ) and Roche ( RHHBY ).) For that reason, even though I have not traded AMGN in almost two years, when I sold out at...